Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Lenalidomide (Primary) ; Alpha galactosylceramide; Dendritic cells
- Indications Multiple myeloma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 20 Jun 2016 Status changed from recruiting to completed.
- 08 May 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.